# ARX788 in Breast Cancer With Low Expression of HER2

> **NCT05018676** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 54 (estimated)

## Conditions studied

- Breast Cancer With Low Expression of HER2

## Interventions

- **DRUG:** ARX788

## Key facts

- **NCT ID:** NCT05018676
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-20
- **Primary completion:** 2022-12-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2022-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05018676

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05018676, "ARX788 in Breast Cancer With Low Expression of HER2". Retrieved via AI Analytics 2026-09-16 from https://api.ai-analytics.org/clinical/NCT05018676. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*